Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients

Figure 2

Cumulative risk of the primary endpoint. The primary endpoint was a composite of death, graft loss, everolimus discontinuation and rejection.